Cargando…

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion

Prolonged cytopenias after chimeric antigen receptor (CAR) T cell therapy are a significant clinical problem and the underlying pathophysiology remains poorly understood. Here, we investigated how (CAR) T cell expansion dynamics and serum proteomics affect neutrophil recovery phenotypes after CD19-d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rejeski, Kai, Perez, Ariel, Iacoboni, Gloria, Blumenberg, Viktoria, Bücklein, Veit L., Völkl, Simon, Penack, Olaf, Albanyan, Omar, Stock, Sophia, Müller, Fabian, Karschnia, Philipp, Petrera, Agnese, Reid, Kayla, Faramand, Rawan, Davila, Marco L., Modi, Karnav, Dean, Erin A., Bachmeier, Christina, von Bergwelt-Baildon, Michael, Locke, Frederick L, Bethge, Wolfgang, Bullinger, Lars, Mackensen, Andreas, Barba, Pere, Jain, Michael D., Subklewe, Marion
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for the Advancement of Science 2023
Materias:	Biomedicine and Life Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516499/ https://www.ncbi.nlm.nih.gov/pubmed/37738350 http://dx.doi.org/10.1126/sciadv.adg3919

Ejemplares similares

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
por: Rejeski, K., et al.
Publicado: (2022)

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
por: Rejeski, Kai, et al.
Publicado: (2022)

P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE
por: Bücklein, V., et al.
Publicado: (2022)

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use
por: Bücklein, Veit, et al.
Publicado: (2023)

Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment
por: Schoeberl, Florian, et al.
Publicado: (2022)

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL
por: Rejeski, Kai, et al.
Publicado: (2023)

Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells
por: Karschnia, Philipp, et al.
Publicado: (2021)

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL
por: Blumenberg, Viktoria, et al.
Publicado: (2023)

P1445: MYTCELL®: AN INTERACTIVE SMARTPHONE APPLICATION FOR CARS AND BITES INCREASES GUIDELINE ACCESSIBILITY AND REDUCES TIME TO APPLY EVIDENCE-BASED PATIENT CARE
por: Blumenberg, V., et al.
Publicado: (2022)

Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy – a case report
por: Rejeski, Kai, et al.
Publicado: (2021)

Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy
por: Rejeski, Kai, et al.
Publicado: (2023)

The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
por: Rejeski, Kai, et al.
Publicado: (2023)

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

Ten things the hematologist wants you to know about CAR-T cells
por: Böll, Boris, et al.
Publicado: (2020)

PB2210: FAVORABLE OUTCOME AFTER SECOND CD19 CAR T INFUSION OF AN IDENTICAL PRODUCT: HOST ENVIRONMENT AND DISEASE CHARACTERISTICS DETERMINE THE OUTCOME OF TREATMENT
por: Frölich, L., et al.
Publicado: (2022)

An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA
por: Rejeski, Kai, et al.
Publicado: (2023)

Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells
por: Karschnia, Philipp, et al.
Publicado: (2022)

S260: IMMUNE EFFECTOR CELL ASSOCIATED HEMATOTOXICITY (ICAHT) FOLLOWING CAR T-CELL THERAPY: INTERNATIONAL SURVEY AND CONSENSUS GUIDELINES ON ITS GRADING, DIAGNOSIS, AND MANAGEMENT ON BEHALF OF EHA AND EBMT
por: Rejeski, Kai, et al.
Publicado: (2023)

S263: CYTOPENIAS, AGE AND CAR-HEMATOTOX SCORE PREDICT THE DEVELOPMENT OF POST CAR T-CELL THERAPY-RELATED MYELOID NEOPLASMS
por: Gurney, Mark, et al.
Publicado: (2023)

Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany
por: Skalt, Daniela, et al.
Publicado: (2022)

Inflammatory abrasion of hematopoietic stem cells: a candidate clue for the post-CAR-T hematotoxicity?
por: Sun, Ting, et al.
Publicado: (2023)

Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment
por: Winkelmann, Michael, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival
por: Winkelmann, Michael, et al.
Publicado: (2022)

Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria
por: Winkelmann, Michael, et al.
Publicado: (2023)

Role of CAR T Cell Metabolism for Therapeutic Efficacy
por: Rial Saborido, Judit, et al.
Publicado: (2022)

Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies
por: Cordas dos Santos, David M., et al.
Publicado: (2022)

Teaching an old dog new tricks: next-generation CAR T cells
por: Tokarew, Nicholas, et al.
Publicado: (2018)

CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
por: Karschnia, Philipp, et al.
Publicado: (2021)

Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy
por: Winkelmann, Michael, et al.
Publicado: (2023)

Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
por: Nixdorf, D., et al.
Publicado: (2023)

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression
por: Rohrbacher, Lisa, et al.
Publicado: (2021)

Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study
por: Ayuk, Francis, et al.
Publicado: (2023)

Functional connectivity MRI provides an imaging correlate for chimeric antigen receptor T-cell-associated neurotoxicity
por: Stoecklein, Sophia, et al.
Publicado: (2023)

Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity
por: Wang, Zhenzhen, et al.
Publicado: (2023)

Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma
por: Sheikh, Semira, et al.
Publicado: (2021)

Complications after CD19+ CAR T-Cell Therapy
por: Penack, Olaf, et al.
Publicado: (2020)

Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy
por: Reimann, Hannah, et al.
Publicado: (2022)

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
por: Albanyan, Omar, et al.
Publicado: (2022)

The race is on: bispecifics vs CAR T cells in B-cell lymphoma
por: Gurumurthi, Ashwath, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vbjflj5ilheef966achese8d3j